Brenton G Mar

List of Publications by Year
in descending order

32 papers	6,745 citations	430442 18 h-index	500791 28 g-index
32 all docs	32 docs citations	32 times ranked	11198 citing authors

#	Article	IF	Citations
1	Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. New England Journal of Medicine, 2014, 371, 2488-2498.	13.9	3,474
2	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125, 1367-1376.	0.6	747
3	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine, 2017, 376, 536-547.	13.9	586
4	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 2691-2698.	0.8	359
5	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	0.8	339
6	CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature, 2009, 459, 1000-1004.	13.7	227
7	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications, 2014, 5, 3469.	5.8	171
8	PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood, 2018, 132, 1095-1105.	0.6	160
9	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. Blood, 2017, 130, 2631-2641.	0.6	102
10	Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with <scp>TP</scp> 53 mutations. EMBO Molecular Medicine, 2017, 9, 498-507.	3.3	86
11	A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31. Oncogene, 2001, 20, 6946-6954.	2.6	71
12	Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia, 2012, 26, 1881-1883.	3.3	70
13	The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia. Blood, 2017, 129, 497-508.	0.6	65
14	The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia, 2011, 25, 1665-1673.	3.3	58
15	The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood, 2017, 130, 433-439.	0.6	50
16	Self-renewal related signaling in myeloid leukemia stem cells. International Journal of Hematology, 2011, 94, 109-117.	0.7	41
17	Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. Journal of Clinical Investigation, 2016, 126, 3827-3836.	3.9	40
18	Novel transcription factors in human CD34 antigenâ€“positive hematopoietic cells. Blood, 2002, 100, 107-119.	0.6	32

#	Article	IF	Citations
19	Membrane-Associated and Secreted Genes in Breast Cancer. Cancer Research, 2004, 64, 8682-8687.	0.4	17
20	Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. Blood, 2021, 138, 318-318.	0.6	16
21	PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy. Journal of Allergy and Clinical Immunology, 2020, 145, AB336.	1.5	15
22	Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). Leukemia Research, 2021, 108, 106606.	0.4	6
23	Knockdown of CCR7 or Its Ligands Causes a Loss of Central Nervous System Involvement in Notch1 Induced T-ALL. Blood, 2008, 112, 199-199.	0.6	4
24	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. Blood, 2016, 128, 986-986.	0.6	3
25	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. Blood, 2019, 134, 2950-2950.	0.6	2
26	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 69-69.	0.6	2
27	Genetic Engineering and Significant Ex-Vivo Expansion of Cord Blood Natural Killer Cells: Implications for Post-Transplant Adoptive Cellular Immunotherapy. Blood, 2008, 112, 209-209.	0.6	1
28	Clonal Hematopoiesis with Somatic Mutations Is a Common, Age-Related Condition Associated with Adverse Outcomes. Blood, 2014, 124, 840-840.	0.6	1
29	Diagnosis and Treatment of Acute Myeloid Leukemia in Children. , 2018, , 359-374.		0
30	Whole exome sequencing of a breast tumor in a patient with Diamond Blackfan anemia. Blood Cells, Molecules, and Diseases, 2021, 89, 102566.	0.6	0
31	Ontogeny-Specific Patterns of Genetic Alterations in Acute Myeloid Leukemia. Blood, 2014, 124, 18-18.	0.6	0
32	SETD2 Heterozygous Loss in Leukemia Leads to Chemotherapy Resistance through Attenuation of the DNA Damage Response. Blood, 2015, 126, 2626-2626.	0.6	0